The bill amends the Idaho Code to update the classifications of controlled substances, specifically focusing on Schedule I, Schedule III, and Schedule IV substances. It introduces new substances to Schedule I, including various fentanyl analogs such as "Alpha'-methyl butyryl fentanyl" and "2',5'-Dimethoxyfentanyl," while removing others like "Alpha-methylfentanyl" and "Beta-methyl fentanyl." Additionally, the bill adds several synthetic cannabinoids and compounds derived from indole and pyrrole structures, including Cumyl PeGACLONE and 5F-EDMB-PINACA. The amendments also modify classifications of depressants and stimulants, incorporating new substances like Clonazolam and Diclazepam, thereby enhancing the regulatory framework to address emerging drug trends.

Moreover, the bill revises the classification of anabolic steroids and human growth hormones, introducing new entries such as 2alpha,17alpha-dimethyl-17beta-hydroxy-5beta-androstan-3-one and 4-chloro-17alpha-methyl-androsta-1,4-diene-3,17beta-diol, while removing outdated substances. It clarifies that anabolic steroids approved by the FDA for nonhuman species will not be classified as controlled substances. The bill establishes penalties for unlawful prescription, dispensing, or possession of anabolic steroids for performance enhancement without medical necessity and includes provisions for hallucinogenic substances. An emergency declaration is included, with the bill set to take effect on July 1, 2025.

Statutes affected:
Bill Text: 37-2705, 37-2709, 37-2711